DB:TQB2

Stock Analysis Report

Executive Summary

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally.


Snowflake Analysis

Mediocre balance sheet and overvalued.


Similar Companies

Share Price & News

How has ImmunoPrecise Antibodies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TQB2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.2%

TQB2

3.3%

DE Life Sciences

9.1%

DE Market


1 Year Return

-10.1%

TQB2

29.7%

DE Life Sciences

-13.1%

DE Market

Return vs Industry: TQB2 underperformed the German Life Sciences industry which returned 28.3% over the past year.

Return vs Market: TQB2 exceeded the German Market which returned -14.3% over the past year.


Shareholder returns

TQB2IndustryMarket
7 Day-7.2%3.3%9.1%
30 Day-0.9%9.8%-1.0%
90 Day26.8%7.9%-20.7%
1 Year-10.1%-10.1%30.9%29.7%-10.6%-13.1%
3 Yearn/a92.5%82.6%-10.7%-18.1%
5 Yearn/a203.7%183.4%-10.7%-22.8%

Price Volatility Vs. Market

How volatile is ImmunoPrecise Antibodies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ImmunoPrecise Antibodies undervalued compared to its fair value and its price relative to the market?

3.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TQB2's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TQB2's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TQB2 is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: TQB2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TQB2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TQB2 is good value based on its PB Ratio (3.4x) compared to the XE Life Sciences industry average (3.9x).


Next Steps

Future Growth

How is ImmunoPrecise Antibodies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ImmunoPrecise Antibodies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has ImmunoPrecise Antibodies performed over the past 5 years?

-42.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TQB2 is currently unprofitable.

Growing Profit Margin: TQB2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TQB2 is unprofitable, and losses have increased over the past 5 years at a rate of -42.2% per year.

Accelerating Growth: Unable to compare TQB2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TQB2 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.1%).


Return on Equity

High ROE: TQB2 has a negative Return on Equity (-54.29%), as it is currently unprofitable.


Next Steps

Financial Health

How is ImmunoPrecise Antibodies's financial position?


Financial Position Analysis

Short Term Liabilities: TQB2's short term assets (CA$7.6M) exceed its short term liabilities (CA$6.5M).

Long Term Liabilities: TQB2's short term assets (CA$7.6M) exceed its long term liabilities (CA$4.7M).


Debt to Equity History and Analysis

Debt Level: TQB2's debt to equity ratio (19.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TQB2's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TQB2 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TQB2 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -46.9% each year


Next Steps

Dividend

What is ImmunoPrecise Antibodies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TQB2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TQB2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TQB2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TQB2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TQB2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Jennifer Bath

2.17s

Tenure

CA$537,682

Compensation

Dr. Jennifer Bath has been the Chief Executive Officer and President of ImmunoPrecise Antibodies Ltd. since February 21, 2018. Dr. Bath served as the Global Director of Client Relations at Aldevron, LLC, w ...


CEO Compensation Analysis

Compensation vs Market: Jennifer's total compensation ($USD384.04K) is about average for companies of similar size in the German market ($USD421.65K).

Compensation vs Earnings: Jennifer's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
James Kuo
Independent Chairman of the Board3.33yrsno datano data
Jennifer Bath
CEO, President & Director2.17yrsCA$537.68k0.060% CA$20.5k
Lisa Helbling
Chief Financial Officer1.25yrsCA$116.04k0.014% CA$4.9k
Charles Wheelock
Chief Technology Officer2yrsCA$332.03k0.0072% CA$2.5k
Jason Orloske
Vice President of Operations1.33yrsCA$75.46kno data
David Orton
Chief Operating Officer3.08yrsno datano data
Yasmina Abdiche
Chief Scientific Officerno datano datano data
Lauren Smith
Vice President of Marketing and Sales3yrsno datano data
Stefan Lang
Chief Business Officer0.50yrno data0.010% CA$3.4k

2.1yrs

Average Tenure

Experienced Management: TQB2's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Kuo
Independent Chairman of the Board3.33yrsno datano data
Jennifer Bath
CEO, President & Director2.17yrsCA$537.68k0.060% CA$20.5k
Brian Lundstrom
Additional Independent Director0.50yrno data0.10% CA$34.0k
Paul Andreola
Independent Director1.42yrsno data4.14% CA$1.4m
Gregory Smith
Independent Director3.75yrsno data0.079% CA$27.1k
Guy Champagne
Member of Advisory Board1.67yrsCA$55.00kno data
Robert Beecroft
Founder & Independent Director24.92yrsCA$21.35k6.25% CA$2.1m
Robert Burke
Independent Director2.33yrsno data0.058% CA$19.7k

2.1yrs

Average Tenure

55yo

Average Age

Experienced Board: TQB2's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TQB2 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.9%.


Top Shareholders

Company Information

ImmunoPrecise Antibodies Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImmunoPrecise Antibodies Ltd.
  • Ticker: TQB2
  • Exchange: DB
  • Founded: 1983
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$51.929m
  • Listing Market Cap: CA$34.109m
  • Shares outstanding: 69.24m
  • Website: https://www.immunoprecise.com

Location

  • ImmunoPrecise Antibodies Ltd.
  • 4837 Amber Valley Parkway
  • Suite 11
  • Fargo
  • North Dakota
  • 58104
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPATSXV (TSX Venture Exchange)YesCommon SharesCACADDec 2016
IPAT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDDec 2016
TQB2DB (Deutsche Boerse AG)YesCommon SharesDEEURDec 2016

Biography

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; and modeling, design, and manufacturing of custom antigen. The company also offers phage-display antibody platforms that generates monoclonal antibodies in a diverse range of species against complex protein structures; Genetic Immunization Platform; and DeepDisplay, a service offering in therapeutic discovery to select rare, fully human antibodies. The company was incorporated in 1983 and is headquartered in Fargo, North Dakota. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/10 09:02
End of Day Share Price2020/04/09 00:00
Earnings2020/01/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.